Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry

Background Previous clinical trials found improved outcome of thrombolytic treatment in patients with ischemic wake‐up stroke (WUS) selected by advanced imaging techniques. The authors assessed the effectiveness of thrombolytic treatment in patients with WUS in a nationwide stroke registry. Methods...

Full description

Bibliographic Details
Main Authors: Mary‐Helen Søyland, Arnstein Tveiten, Agnethe Eltoft, Halvor Øygarden, Torunn Varmdal, Bent Indredavik, Ellisiv B. Mathiesen
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.032309
_version_ 1827342075867168768
author Mary‐Helen Søyland
Arnstein Tveiten
Agnethe Eltoft
Halvor Øygarden
Torunn Varmdal
Bent Indredavik
Ellisiv B. Mathiesen
author_facet Mary‐Helen Søyland
Arnstein Tveiten
Agnethe Eltoft
Halvor Øygarden
Torunn Varmdal
Bent Indredavik
Ellisiv B. Mathiesen
author_sort Mary‐Helen Søyland
collection DOAJ
description Background Previous clinical trials found improved outcome of thrombolytic treatment in patients with ischemic wake‐up stroke (WUS) selected by advanced imaging techniques. The authors assessed the effectiveness of thrombolytic treatment in patients with WUS in a nationwide stroke registry. Methods and Results Using propensity score matching, the authors assessed the effectiveness and safety of thrombolytic treatment versus no thrombolytic treatment in 726 patients (363 matched pairs) with WUS in the Norwegian Stroke Registry in 2014 to 2019. Thrombolytic treatment in WUS versus known‐onset stroke was compared in 730 patients (365 matched pairs). Functional outcomes were assessed by the modified Rankin Scale (mRS) at 3 months. A significant benefit of thrombolytic treatment in WUS was seen in ordinal analysis (odds ratio [OR], 1.48 [95% CI, 1.15–1.91]; P=0.003) and for mRS 0 to 2 (OR, 1.81 [95% CI, 1.29–2.52]; P=0.001) but not for mRS 0 or 1 (OR, 1.32 [95% CI, 1.00–1.74]; P=0.050). The proportion of patients with mRS 0 or 1 was lower in patients with WUS who underwent thrombolysis versus those with known‐onset stroke (50.4% versus 59.5%; OR, 0.69 [95% CI, 0.52–0.93]; P=0.013), while outcomes were similar between groups for mRS 0 to 2 and ordinal analysis. Symptomatic intracranial hemorrhage after thrombolytic treatment occurred in 4.4% of patients with WUS and 3.9% of patients with known‐onset stroke (OR, 1.14 [95% CI, 0.54–2.41]; P=0.726). Conclusions Thrombolytic treatment in patients with WUS was associated with improved functional outcome compared with patients with no thrombolytic treatment and was not associated with increased rates of symptomatic intracranial hemorrhage compared with known‐onset stroke. The results indicate that thrombolytic treatment is effective and safe in WUS in a real‐life setting.
first_indexed 2024-03-07T22:02:27Z
format Article
id doaj.art-a4975e62f5e84a7e90fc0c5afa763599
institution Directory Open Access Journal
issn 2047-9980
language English
last_indexed 2024-03-07T22:02:27Z
publishDate 2024-02-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj.art-a4975e62f5e84a7e90fc0c5afa7635992024-02-24T04:06:35ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802024-02-0113310.1161/JAHA.123.032309Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke RegistryMary‐Helen Søyland0Arnstein Tveiten1Agnethe Eltoft2Halvor Øygarden3Torunn Varmdal4Bent Indredavik5Ellisiv B. Mathiesen6Department of Neurology Hospital of Southern Norway Kristiansand NorwayDepartment of Neurology Hospital of Southern Norway Kristiansand NorwayDepartment of Clinical Medicine UiT The Arctic University of Norway Tromsø NorwayDepartment of Neurology Hospital of Southern Norway Kristiansand NorwayNorwegian University of Science and Technology Trondheim NorwayNorwegian University of Science and Technology Trondheim NorwayDepartment of Clinical Medicine UiT The Arctic University of Norway Tromsø NorwayBackground Previous clinical trials found improved outcome of thrombolytic treatment in patients with ischemic wake‐up stroke (WUS) selected by advanced imaging techniques. The authors assessed the effectiveness of thrombolytic treatment in patients with WUS in a nationwide stroke registry. Methods and Results Using propensity score matching, the authors assessed the effectiveness and safety of thrombolytic treatment versus no thrombolytic treatment in 726 patients (363 matched pairs) with WUS in the Norwegian Stroke Registry in 2014 to 2019. Thrombolytic treatment in WUS versus known‐onset stroke was compared in 730 patients (365 matched pairs). Functional outcomes were assessed by the modified Rankin Scale (mRS) at 3 months. A significant benefit of thrombolytic treatment in WUS was seen in ordinal analysis (odds ratio [OR], 1.48 [95% CI, 1.15–1.91]; P=0.003) and for mRS 0 to 2 (OR, 1.81 [95% CI, 1.29–2.52]; P=0.001) but not for mRS 0 or 1 (OR, 1.32 [95% CI, 1.00–1.74]; P=0.050). The proportion of patients with mRS 0 or 1 was lower in patients with WUS who underwent thrombolysis versus those with known‐onset stroke (50.4% versus 59.5%; OR, 0.69 [95% CI, 0.52–0.93]; P=0.013), while outcomes were similar between groups for mRS 0 to 2 and ordinal analysis. Symptomatic intracranial hemorrhage after thrombolytic treatment occurred in 4.4% of patients with WUS and 3.9% of patients with known‐onset stroke (OR, 1.14 [95% CI, 0.54–2.41]; P=0.726). Conclusions Thrombolytic treatment in patients with WUS was associated with improved functional outcome compared with patients with no thrombolytic treatment and was not associated with increased rates of symptomatic intracranial hemorrhage compared with known‐onset stroke. The results indicate that thrombolytic treatment is effective and safe in WUS in a real‐life setting.https://www.ahajournals.org/doi/10.1161/JAHA.123.032309cerebrovascular disease/strokeepidemiologyischemic strokethrombolytic treatmentwake‐up stroke
spellingShingle Mary‐Helen Søyland
Arnstein Tveiten
Agnethe Eltoft
Halvor Øygarden
Torunn Varmdal
Bent Indredavik
Ellisiv B. Mathiesen
Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
cerebrovascular disease/stroke
epidemiology
ischemic stroke
thrombolytic treatment
wake‐up stroke
title Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry
title_full Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry
title_fullStr Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry
title_full_unstemmed Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry
title_short Thrombolytic Treatment in Wake‐Up Stroke: A Propensity Score–Matched Analysis of Treatment Effectiveness in the Norwegian Stroke Registry
title_sort thrombolytic treatment in wake up stroke a propensity score matched analysis of treatment effectiveness in the norwegian stroke registry
topic cerebrovascular disease/stroke
epidemiology
ischemic stroke
thrombolytic treatment
wake‐up stroke
url https://www.ahajournals.org/doi/10.1161/JAHA.123.032309
work_keys_str_mv AT maryhelensøyland thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry
AT arnsteintveiten thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry
AT agnetheeltoft thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry
AT halvorøygarden thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry
AT torunnvarmdal thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry
AT bentindredavik thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry
AT ellisivbmathiesen thrombolytictreatmentinwakeupstrokeapropensityscorematchedanalysisoftreatmenteffectivenessinthenorwegianstrokeregistry